Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

Biogen just can’t quit Alzheimers, licensing another drug from Pfizer

Biogen just can’t quit Alzheimer’s, licensing another drug from Pfizer

Snaps up clinical-stage candidate for $75m upfront. Biogen’s mixed fortunes in Alzheimer’s drug development haven’t stopped it snapping up a clinical-stage candidate for the disease from ... Biogen – which has been leading the charge among

Latest news

More from news
Approximately 61 fully matching, plus 320 partially matching documents found.

Latest Intelligence

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    The test works by identifying amyloid-beta (Abeta) proteins, which build up on the brains of those living with Alzheimer’s and which have a key link to the disease, although ... Alzheimer’s R&D has had to diversify as companies and researchers become

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimers disease

    Yet more than 100 years after the discovery of Alzheimer’s disease, we still do not have a cure. ... Today, Alzheimer’s disease is typically diagnosed once symptoms are already clinically present.

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimers disease R&D?

    How past failures and emerging biology are reshaping drug development. Over the past 15 years, the best-resourced drug development teams on earth have spent billions on Alzheimer’s disease. ... And there is scope to improve the lives of Alzheimer’s

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimers drug discovery

    A phase I dose escalation study of AL002 for patients with Alzheimer’s disease, as part of a global strategic partnership with AbbVie, is ongoing. ... Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders,

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimers disease – is Europe prepared if a breakthrough treatment becomes available?

    Currently, there is no Alzheimer’s disease- modifying treatment available but there are several therapies in development. ... If appropriate, they would be referred to treatment, which would reduce the risk of progression from MCI to manifest dementia

More from intelligence
Approximately 3 fully matching, plus 28 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

  • Digital therapeutics and their impact on society

    Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic? ... This is in part due to the explosive, bordering on unmanageable, increase in chronic

  • Are we ready for an Alzheimer's disease modifying treatment

    Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. ... However, Alzheimer’s disease-modifying treatments (DMTs) have not progressed as much in the last 15 years as we all hoped.

  • Diagnosing the lag in neuropsychiatric treatments

    Europe spends £690 billion a year on brain disorders, more than both cardiovascular disease and oncology combined. ... Neurological and psychiatric disorders (collectively known as neuropsychiatric disorders), such as Alzheimer’s disease and

  • 'Fake news': battling misinformation in healthcare

    An article published just three days later, again from ‘The Telegraph’ , plays on the  growing threat of Alzheimer’s. ... The article is entitled ‘Alzheimer’s disease can be spotted through simple eye test’ and whilst this article is based

  • Havas Lynx shines a spotlight on carers

    Commenting on the white paper’s findings, Havas Lynx CEO, Dave Hunt, said:. ... References:. Alzheimer’s Disease International (2013) http://bit.ly/2nPw6QK (Accessed April 2017). Carers UK (2015)   (Accessed April 2017).

More from PMHub
Approximately 2 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics